Related Experiment Video
Updated: May 13, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Study on prohibition of high mobility group chromosomal protein N2 against human oral squamous cell carcinoma in
Xiaoqian Dong1, Xiqian Liu, Yonghong Zhang
1State Key Laboratory of Oral Diseases, Sichuan University, Chengdu 610041, China.
Objective:
Take human oral squamous cell carcinoma Tca8113 as experimental model, and study the anti oral squamous cell carcinoma activity of high mobility group chromosomal protein N2 (HMGN2) molecule.
Methods:
Train a large number of recombinant human HMGN2 expression vector Escherichia coli BL21. HMGN2 was expressed under isopropyl-1-thio-beta-galactopyranoside (IPTG) induction and purified by B-PER GST Fusion Protein Purification Kit. A variety of concentrations HMGN2 were added to cell culture medium, cells were tested by MTT, Hoechst 33342 fluorescence staining, flow cytometry assay and Western-blot.
Results:
MTT results proved that HMGN2 could significantly inhibit human oral squamous cell carcinoma Tca8113 growth. Hoechst 33342 fluorescence staining, flow cytometry assay test and Western-blot proved HMGN2 could make Tca8113 cells morphological change, make Tca8113 cells block in S period of cell cycle and strongly promote Tca8113 cells to apoptosis.
Conclusion:
HMGN2 can promote apoptosis of oral squamous cell carcinoma cells.
Insights
High mobility group chromosomal protein N2 (HMGN2) effectively inhibits oral squamous cell carcinoma growth by promoting cancer cell apoptosis. This study demonstrates HMGN2's potential as an anti-cancer therapeutic agent.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oral squamous cell carcinoma (OSCC) is a prevalent cancer with limited treatment options.
- High mobility group chromosomal protein N2 (HMGN2) is a chromatin-associated protein with poorly understood roles in cancer.
Purpose of the Study:
- To investigate the anti-cancer activity of HMGN2 on human oral squamous cell carcinoma Tca8113 cells.
- To elucidate the molecular mechanisms underlying HMGN2's effects on OSCC.
Main Methods:
- Recombinant human HMGN2 was expressed in E. coli and purified.
- Tca8113 cells were treated with varying concentrations of HMGN2.
- Cell viability (MTT assay), apoptosis (Hoechst 33342 staining, flow cytometry), cell cycle progression, and protein expression (Western blot) were analyzed.
Main Results:
- HMGN2 significantly inhibited the proliferation of Tca8113 cells.
- HMGN2 induced morphological changes indicative of apoptosis in Tca8113 cells.
- HMGN2 treatment led to cell cycle arrest at the S phase and promoted apoptosis.
Conclusions:
- HMGN2 exhibits significant anti-oral squamous cell carcinoma activity.
- HMGN2 promotes apoptosis in oral squamous cell carcinoma cells, suggesting its potential as a therapeutic target.
